GenSight Biologics Announces Interim Financial Results for H1 2024 and Shares Business Updates
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has released its…
Catherine Owen Adams Appointed CEO of Acadia Pharmaceuticals, Succeeding Steve Davis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the appointment of Catherine Owen Adams as its new Chief Executive Officer (CEO), succeeding Steve Davis. Adams will also join the company’s Board…
WHO Endorses CINtec PLUS Test, Highlighting Roche’s Role in Cervical Cancer Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the World Health Organization (WHO) has included dual-stain cytology testing in its updated cervical cancer prevention guidelines. The Roche CINtec® PLUS Cytology…
Pearsanta Partners with Evofem for U.S. Endometriosis Diagnostic Launch in Mid-2025
Aditxt, Inc. (NASDAQ: ADTX), an innovation-driven company focused on accelerating healthcare advancements, announced today that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem…
Pfizer, BioNTech Get CHMP Approval for Omicron KP.2-Adapted Vaccine in EU
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval…
Ipsen’s Iqirvo Approved in EU as First New Treatment for PBC in a Decade
Ipsen (Euronext: IPN; ADR: IPSEY) has announced that the European Commission has granted conditional approval for Iqirvo® (elafibranor) 80mg tablets. Iqirvo is approved for the treatment of primary biliary cholangitis…
Governments Advance Pandemic Agreement for Future Emergency Preparedness
Negotiations on the world’s first agreement to safeguard people from future pandemics, led by the World Health Organization (WHO), made significant strides during the latest round of discussions, which concluded…
Elanco Launches FDA-Approved Zenrelia for Canine Dermatology
Elanco Animal Health Incorporated (NYSE: ELAN) has announced that the U.S. Food and Drug Administration (FDA) has approved Zenrelia™, a once-daily oral JAK inhibitor for the control of pruritus (itching)…
Positive CHMP Opinion Granted to Samsung Bioepis and Biogen for Aflibercept Biosimilar, OPUVIZ
Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion…
US Approves Sarclisa as First Anti-CD38 Therapy for Non-Transplant Multiple Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple…
Pfizer and BioNTech Get Favorable CHMP Opinion for Omicron KP.2-Adjusted COVID-19 Vaccine in the EU
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Fasenra Receives U.S. Approval for Treating Eosinophilic Granulomatosis with Polyangiitis
AstraZeneca’s Fasenra (benralizumab) has received U.S. approval for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially fatal immune-mediated vasculitis that can damage multiple organs. This…